H.C. Wainwright analyst Brandon Folkes initiated coverage of Rein Therapeutics (RNTX) with a Buy rating and $10 price target The shares can outperform over the next 12 months given the company’s “potential best-in-class pipeline,” the analyst tells investors in a research note. The firm expects the biggest share catalyst to be the initial data readout of the Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNTX:
- Rein Therapeutics announces publication of data on LTI-03 in IPF
- Rein Therapeutics Secures Second Advance in Funding Deal
- Rein Therapeutics files to sell 10M shares of common stock for holders
- Home Depot reports Q2 results, SoftBank invests $2B in Intel: Morning Buzz
- Palo Alto upgraded, Li Auto downgraded: Wall Street’s top analyst calls